Buichi Fujitani
About
In The Last Decade
Buichi Fujitani
45 papers receiving 612 citations
Peers
Comparison fields: 5 of 86
- Molecular Biology 224
- Organic Chemistry 117
- Pharmacology 103
- Cellular and Molecular Neuroscience 75
- Physiology 70
Countries citing papers authored by Buichi Fujitani
This map shows the geographic impact of Buichi Fujitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Buichi Fujitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Buichi Fujitani more than expected).
Fields of papers citing papers by Buichi Fujitani
This network shows the impact of papers produced by Buichi Fujitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Buichi Fujitani. The network helps show where Buichi Fujitani may publish in the future.
Co-authorship network of co-authors of Buichi Fujitani
This figure shows the co-authorship network connecting the top 25 collaborators of Buichi Fujitani. A scholar is included among the top collaborators of Buichi Fujitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Buichi Fujitani. Buichi Fujitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 104 | |
| 2 | 1 | |
| 3 | 47 | |
| 4 | 7 | |
| 5 | 9 | |
| 6 | 5 | |
| 7 | 11 | |
| 8 | 2 | |
| 9 | 10 | |
| 10 | 11 | |
| 11 | 14 | |
| 12 | 3 | |
| 13 | General pharmacology of the novel antiepileptic compound zonisamide. 2nd communication: effects on cardiovascular, visceral, renal and blood functions. | 9 |
| 14 | General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood. | 1 |
| 15 | 14 | |
| 16 | 1 | |
| 17 | 2 | |
| 18 | Pharmacological evaluation of ONO 1206, a prostaglandin E1 derivative, as antianginal agent. | 11 |
| 19 | 19 | |
| 20 | 55 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.